Tokyo, Feb. 3 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060553) titled 'A Multicenter Collaborative Study on Molecular Profiling and Biomarker Analysis for the Development of Personalized Perioperative Treatment in Resectable Solid Tumors' on Feb. 2.

Study Type: Observational

Primary Sponsor: Institute - National Cancer Center

Condition: Condition - Resectable solid tumor Classification by malignancy - Malignancy Genomic information - YES

Objective: Narrative objectives1 - The aim of this study is to perform molecular profiling of blood and tissue samples in patients with resectable solid tumors undergoing curative treatment, and to integrate these data with clinical information to identify biomarkers that reflect the molecular biological characteristics. Basic objectives2 - Others

Eligibility: Age-lower limit - 18 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - 1. The patient is 18 years of age or older at the time of obtaining consent. 2. The patient has been diagnosed with one of the following resectable malignant solid tumors, at clinical stage I-IV Gastric cancer, pancreatic cancer, liver cancer, breast cancer, ovarian cancer, bladder cancer, or endometrial cancer 3. The patient is scheduled to undergo curative resection or curative chemotherapy and or chemoradiotherapy. *1 4. The patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. 5. Written informed consent for participation in this study has been obtained from the patient.

*1 Patients who are scheduled for curative resection are eligible even if they undergo preoperative chemoradiotherapy or chemotherapy. Key exclusion criteria - 1. The patient has double cancer.*1 2. The patient is pregnant. 3. The patient has a history of, or concurrent, other malignancies within 3 years prior to enrollment. 4. The patient has serious comorbidities (e.g., uncontrolled diabetes or infections, symptomatic interstitial pneumonia or pulmonary fibrosis, etc.). 5. The patient is deemed by the principal investigator to be otherwise inappropriate for participation in this study.

*1: Includes synchronous or multiple cancers, as well as metachronous cancers with a disease-free interval of less than 3 years. However, the following histories are not considered active double/multiple cancers, even if the disease-free interval is less than 3 years, provided they have been completely resected and correspond to the pathological stages listed below:

Gastric cancer (adenocarcinoma, common type): Stage 0-I Colon cancer (adenocarcinoma): Stage 0-I Rectal cancer (adenocarcinoma): Stage 0-I Esophageal cancer (squamous cell carcinoma, adenosquamous carcinoma, basaloid carcinoma): Stage 0 Breast cancer (DCIS, LCIS): Stage 0 Breast cancer (invasive ductal carcinoma, invasive lobular carcinoma, Paget disease): Stage 0-IIA Endometrial cancer (endometrioid adenocarcinoma, mucinous adenocarcinoma): Stage I Prostate cancer (adenocarcinoma): Stage I-II Cervical cancer (squamous cell carcinoma): Stage 0 Thyroid cancer (papillary carcinoma, follicular carcinoma): Stage I-III Renal cancer (clear cell carcinoma, chromophobe carcinoma): Stage I Other lesions equivalent to carcinoma in situ of mucosal origin

Staging is based on the UICC-TNM Classification, 8th Edition. Target Size - 1400

Recruitment Status: Recruitment status - Open public recruiting Date of protocol fixation - 2026 Year 01 Month 05 Day Date of IRB - 2026 Year 01 Month 15 Day Anticipated trial start date - 2026 Year 02 Month 02 Day Last follow-up date - 2034 Year 03 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069265

Disclaimer: Curated by HT Syndication.